Medtronic and health insurer Aetna have agreed to use clinical outcomes as the basis of payment for Medtronic's insulin pump systems, but financial details of the agreement were not disclosed. The deal will initially concentrate on measuring A1C targets of diabetes patients who use the pumps and may assess hypoglycemia episodes, patient satisfaction, time in proper glycemic range and other measures in the future, said Suzanne Winter, vice president of the Medtronic diabetes group in the Americas.
Medtronic, Aetna enter outcomes-based agreement for insulin pumps
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.